Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-1707 in early Alzheimer's disease
CTR20234283Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1707 in Alzheimer's disease (AD), sponsored by Hengrui Therapeutics. Started Apr 2024; status: terminated.
02
Drugs
SHR-1707
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20234283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234283.